[go: up one dir, main page]

HK1029099A1 - 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies - Google Patents

2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies Download PDF

Info

Publication number
HK1029099A1
HK1029099A1 HK00106848A HK00106848A HK1029099A1 HK 1029099 A1 HK1029099 A1 HK 1029099A1 HK 00106848 A HK00106848 A HK 00106848A HK 00106848 A HK00106848 A HK 00106848A HK 1029099 A1 HK1029099 A1 HK 1029099A1
Authority
HK
Hong Kong
Prior art keywords
acid
preparation
amino
phc
fluoro
Prior art date
Application number
HK00106848A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1029099B (en
Inventor
Fanto Nicola
Piero Moretti Gian
Foresta Piero
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HK1029099A1 publication Critical patent/HK1029099A1/en
Publication of HK1029099B publication Critical patent/HK1029099B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (6)

  1. 2-Aminotetralin mit der Formel (I) oder dessen pharmakologisch akzeptablen Salze mit Formel (II) worin bedeuten:
    R Methyl;
    R1 Acetyl;
    R2 Wasserstoff;
    und X- das monovalente Anion einer pharmakologisch akzeptablen Säure.
  2. Verbindung nach Anspruch 1, worin das monovalente Anion einer pharmakologisch akzeptablen Säure ausgewählt ist aus Chlorid, Bromid, Orotat, saurem Aspartat, saurem Citrat, saurem Phosphat, Fumarat und saurem Fumarat, Lactat, Maleat und saurem Maleat, saurem Oxalat, saurem Sulfat, Glucosephosphat, Tartrat und saurem Tartrat.
  3. Verwendung der Verbindung nach Anspruch 1 oder 2 zur Herstellung eines Medikamentes zur Verhinderung und therapeutischen Behandlung von Entzündungs- und/oder Autoimmunerkrankungen, die durch Entzündungszytokine induziert sind.
  4. Verwendung nach Anspruch 3, worin die Pathologien ausgewählt sind aus der Gruppe, bestehend aus rheumatoider Arthritis, Pankreatitis, entzündlichen Darmerkrankungen, systemischem Lupus erythematosus, Glomerulonephritis und Encephalomyelitis.
  5. Verwendung nach Anspruch 3, worin die Pathologie septischer Schock ist.
  6. Oral oder parenteral verabreichbare pharmazeutische Zusammensetzung, umfassend eine Verbindung nach Anspruch 1 oder 2 als aktiver Bestandteil und einen pharmazeutisch akzeptablen Träger und/oder Verdünnungsmittel.
HK00106848.1A 1997-09-22 1998-09-22 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies HK1029099B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM970568 1997-09-22
IT97RM000568A IT1294931B1 (it) 1997-09-22 1997-09-22 Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella
PCT/IT1998/000252 WO1999015494A1 (en) 1997-09-22 1998-09-22 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies

Publications (2)

Publication Number Publication Date
HK1029099A1 true HK1029099A1 (en) 2001-03-23
HK1029099B HK1029099B (en) 2004-07-23

Family

ID=

Also Published As

Publication number Publication date
CN1145606C (zh) 2004-04-14
KR100583805B1 (ko) 2006-05-26
AU738565B2 (en) 2001-09-20
US6849663B2 (en) 2005-02-01
JP2001517649A (ja) 2001-10-09
KR20010030671A (ko) 2001-04-16
US20030158266A1 (en) 2003-08-21
EP1017667B1 (de) 2003-11-19
ES2210820T3 (es) 2004-07-01
JP4181301B2 (ja) 2008-11-12
US20020123652A1 (en) 2002-09-05
DK1017667T3 (da) 2004-03-29
BR9812368A (pt) 2000-09-19
ITRM970568A1 (it) 1999-03-22
DE69819922T2 (de) 2004-09-02
US20030229148A1 (en) 2003-12-11
US7041703B2 (en) 2006-05-09
PT1017667E (pt) 2004-04-30
CA2303943A1 (en) 1999-04-01
AU9366298A (en) 1999-04-12
NZ503492A (en) 2002-08-28
DE69819922D1 (de) 2003-12-24
WO1999015494A1 (en) 1999-04-01
EP1017667A1 (de) 2000-07-12
CN1276782A (zh) 2000-12-13
ATE254595T1 (de) 2003-12-15
IT1294931B1 (it) 1999-04-23

Similar Documents

Publication Publication Date Title
EP1017667B1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
EP0693475A1 (de) 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
HK1046400A1 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
KR19990022572A (ko) 약제로서의 (ｒ)-(ｚ)-1-아자비시클로[2.2.1]헵탄-3-온,ｏ-[3-(3-메톡시페닐)-2-프로피닐]옥심 말레산염
IL94452A (en) Aryloxyphenylpropylamines their preparation and pharmaceutical compositions containing them
EP0442850A1 (de) Ester von Acyl L-Carnitin mit Gamma-Hydroxybuttersäure und diese enthaltende pharmazeutische Zusammensetzungen zur Inhibierung von neuronaler Degeneration und zur Behandlung von Koma
HK1005859B (en) Esters of acyl l-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma
US4289787A (en) Quaternary ammonium antiarrhythmic drugs
JP2687977B2 (ja) アリールオキシフエニルプロピルアミンおよびその製造方法および用途
JPH05201987A (ja) 新規なベンゾモルファン類およびその薬理組成物としての利用
HK1029099B (en) 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
EP0968174B1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
HK1000541B (en) Benzene derivates, their preparation and pharmaceutical compositions containing them
WO1998033762A9 (en) Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock
US4053632A (en) Compounds of spiro-amine type and methods for their use
MXPA00002780A (en) 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
HK1025558B (en) Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock
US4395410A (en) Quaternary ammonium antiarrhythmic drugs
AU697954C (en) (R)-(Z)-1-azabicyclo{2.2.1}heptan-3-one,o-{3-(3-methoxypheny l)-2-propynyl}oxime maleate as a pharmaceutical agent
JP2001517618A (ja) 炎症性および／または自己免疫疾患の治療的処置のための医薬組成物を調製するのに適した６，７−置換２−アミノテトラリンの使用
HK1026197A1 (en) Pharmaceutically-active dimethyl-(3-aryl-but-3-enyl)-amine compounds
CS232349B1 (cs) 1-fenyl-3-(3,4-dihydroxyfenyl)-2-propy!aminy, jejich hydrobromidy a způsob jejich přípravy

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090922